摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(7-amino-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-O5-phosphono-β-D-1-deoxy-ribofuranose | 55612-44-7

中文名称
——
中文别名
——
英文名称
1-(7-amino-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-O5-phosphono-β-D-1-deoxy-ribofuranose
英文别名
8-Aza-adenosine-5'-monophosphate;[(2R,3S,4R,5R)-5-(7-aminotriazolo[4,5-d]pyrimidin-3-yl)-3,4-dihydroxyoxolan-2-yl]methyl dihydrogen phosphate
1-(7-amino-[1,2,3]triazolo[4,5-<i>d</i>]pyrimidin-3-yl)-<i>O</i><sup>5</sup>-phosphono-β-<i>D</i>-1-deoxy-ribofuranose化学式
CAS
55612-44-7
化学式
C9H13N6O7P
mdl
——
分子量
348.212
InChiKey
AQNUCRJICYNRCK-UUOKFMHZSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -3.9
  • 重原子数:
    23
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    199
  • 氢给体数:
    5
  • 氢受体数:
    12

反应信息

  • 作为产物:
    描述:
    [[(2R,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2S,3R,4S,5S)-5-(7-aminotriazolo[4,5-d]pyrimidin-3-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate;azane 生成 1-(7-amino-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl)-O5-phosphono-β-D-1-deoxy-ribofuranose
    参考文献:
    名称:
    TONO-OKA, SHUICHI;AZUMA, ICHIRO, J. HETEROCYCL. CHEM., 26,(1989) N, C. 339-343
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Complexes of RNA and cationic peptides for transfection and for immunostimulation
    申请人:CureVac GmbH
    公开号:EP2484770A1
    公开(公告)日:2012-08-08
    The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide has a length of 8 to 15 amino acids and has the empirical formula (Arg)l;(;Lys)m;(His)n;(Orn)o;(Xaa)x with the majority of the residues being selected from Arg, Lys, His, Orn. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed RNA. Additionally, pharmaceutical compositions and kits comprising the inventive complexed RNA, as well as the use of the inventive complexed RNA for transfecting a cell, tissue or an organism and/or for modulating, preferably inducing or enhancing, an immune response are disclosed herein.
    本发明涉及一种复合 RNA,包括至少一种与一种或多种寡肽复合的 RNA,其中寡肽的长度为 8 至 15 个氨基酸,具有经验式 (Arg)l;(;Lys)m;(His)n;(Orn)o;(Xaa)x,大部分残基选自 Arg、Lys、His、Orn。本发明进一步涉及一种转染细胞或生物体的方法,从而应用本发明的复合 RNA。此外,本文还公开了包含本发明络合 RNA 的药物组合物和试剂盒,以及本发明络合 RNA 用于转染细胞、组织或生物体和/或调节、优选诱导或增强免疫反应的用途。
  • Cyclic di-nucleotide compounds as STING agonists
    申请人:Merck Sharp & Dohme Corp.
    公开号:US10759825B2
    公开(公告)日:2020-09-01
    A class of polycyclic compounds of general formula (I), of general formula (I′), or of general formula (I″), wherein Base1, Base2, Y, Ya, Xa, Xa1, Xb, Xb1, Xc, Xc1, Xd, Xd1, R1, R1a, R2, R2a, R3, R4, R4a, R5, R6, R6a, R7, R7a, R8, and R8a are defined herein, that may be useful as inductors of type I interferon production, specifically as STING active agents, are provided. Also provided are processes for the synthesis and use of compounds.
    一类通式(I)、通式(I′)或通式(I″)的多环化合物,其中Base1、Base2、Y、Ya、Xa、Xa1、Xb、Xb1、Xc、Xc1、Xd、Xd1、R1、R1a、R2、本文定义的 R2a、R3、R4、R4a、R5、R6、R6a、R7、R7a、R8 和 R8a 可用作 I 型干扰素产生的诱导剂,特别是 STING 活性剂。还提供了合成和使用这些化合物的工艺。
  • COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION
    申请人:Curevac GmbH
    公开号:EP2188379A1
    公开(公告)日:2010-05-26
  • COMPLEXES OF RNA AND CATIONIC PEPTIDES FOR TRANSFECTION AND FOR IMMUNOSTIMULATION
    申请人:CureVac AG
    公开号:US20160184406A1
    公开(公告)日:2016-06-30
    The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide, which has the function of cell-penetrating peptide (CPP), has a length of 8 to 15 amino acids and has the empirical formula (Arg) l ; (Lys) m ; (His) n ; (Om) o ; (Xaa) x with the majority of residues being selected from Arg, Lys, His, Om. The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed RNA. Additionally, pharmaceutical compositions and kits comprising the inventive complexed RNA, as well as the use of the inventive complexed RNA for transfecting a cell, tissue or an organism and/or for modulating, preferably inducing or enhancing, an immune response are disclosed herein.
  • METHODS OF TREATING PHENYLKETONURIA WITH MRNA ENCODING PHENYLALANINE HYDROXYLASE (PAH)
    申请人:CureVac AG
    公开号:US20190167808A1
    公开(公告)日:2019-06-06
    The present invention relates to a complexed RNA, comprising at least one RNA complexed with one or more oligopeptides, wherein the oligopeptide has a length of 8 to 15 amino acids and has the empirical formula (Arg) l ;(;Lys) m ;(His) n ;(Orn) o ;(Xaa) x . The invention further relates to a method for transfecting a cell or an organism, thereby applying the inventive complexed RNA. Additionally, pharmaceutical compositions and kits comprising the inventive complexed RNA, as well as the use of the inventive complexed RNA for transfecting a cell, tissue or an organism and/or for modulating, preferably inducing or enhancing, an immune response are disclosed herein.
查看更多